Buy Park Medi World Ltd For Target Rs. 350 by Choice Institutional Equities Ltd
PARKHOSP continues to expand its footprint across North India while strengthening its existing clusters. With the aim of assessing its growth strategy and operational execution, we visited the company. We met with the management of PARKHOSP, Mr. Sudesh Sharma - Chief Strategy Officer and Mr. Saurabh Pant – Head of Investor Relations. Additionally, we visited the company's Sector 47 and Palam Vihar facilities.
The interaction provided valuable insights into the company's expansion strategy across existing and new markets, including the upcoming Park Hospital Platinum facility in Gurugram and the recently-acquired Medicity Hospital in Rudrapur. The management reiterated its focus on scalable cluster-led growth, disciplined capital allocation, operational efficiency and strengthening its presence in underpenetrated healthcare markets, while maintaining its long-term aspiration of reaching 10,000 beds by FY33.
Valuation: We continue to value the company at 18x EV/EBITDA on FY28E and hence maintain our ‘BUY’ rating with a target price of INR 350.
Key Highlight
* The recently-announced 100-bed Park Hospital Platinum will be adjacent (~100 metres) to the existing 225-bed Palam Vihar hospital, requiring a capex of INR 25Cr with operations expected to commence in November this year
* The expansion is aimed at decongesting the existing Palam Vihar hospital, which operated at ~86% occupancy in FY26 and generated ~INR 25Cr in revenue, indicating a strong demand for additional capacity in the Gurugram market
* With the commissioning of Park Hospital Platinum, the group's consolidated Gurugram capacity will increase to 750 beds, further strengthening its position in one of North India's most competitive healthcare markets
* Acquired the 330-bed Medicity Hospital, Rudrapur (Uttarakhand) for INR 1.77 Bn, marking the group's entry into Uttarakhand ? Operations at the Rudrapur hospital are expected to commence by next month-end; all 330 beds are likely to be operational from Day 1, allowing for immediate scale-up
* For the Rudrapur Hospital, the management targets INR 1 Bn revenue, ~20% EBITDA margin and ~12% PAT margin in Year 1, improving to INR 1.4 bn revenue, ~25% EBITDA margin and ~15% PAT margin in Year 2 through higher occupancy, ARPOB expansion and a richer super-specialty mix
* 100% asset ownership, an efficient bed mix, procurement scale benefits and industry-low capex of ~INR 34–35 lakh per bed enable the company to deliver affordable tertiary and quaternary care while maintaining healthy profitability
* The cluster-based operating model remains a key differentiator, enabling neighbouring hospitals to share doctors, specialised equipment and operational resources, improving utilisation, recruitment and overall operating efficiency
* Total capacity is expected to reach ~5,590 beds by March 2028, supported by ongoing integration of acquired hospitals and expansion of existing facilities, while the management continues to aspire for 10,000 beds by FY33
* The acquisition strategy remains focussed on underpenetrated, highgrowth healthcare markets, with evaluation based on strategic location, healthcare infrastructure gaps, expansion potential and the availability of distressed assets at attractive valuation
* The management expects government receivable days to improve, from the existing ~3 months to below 100 days, supporting stronger working capital efficiency
* The management expects the long-term payor mix to stabilise at ~75% government patients; the remainder comprises insurance and self-pay patients.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
